HealthcareServices

Global Acute Respiratory Distress Syndrome (ARDS) Market Set for Strong Expansion, Reaching $2.42 Billion With 11.7% CAGR by 2030

February 19, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the acute respiratory distress syndrome (ards) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Acute Respiratory Distress Syndrome (ARDS) Market in 2030?

The acute respiratory distress syndrome (ards) market has experienced rapid expansion over recent years. Its size is projected to increase from $1.41 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to a rising incidence of respiratory infections, a growing hospital ICU infrastructure, increasing awareness of ARDS management protocols, limited availability of advanced ventilation devices, and the adoption of supportive care practices.

The market size for acute respiratory distress syndrome (ards) is projected for substantial expansion over the coming years, reaching $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is driven by technological progress in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS treatments, the global proliferation of critical care units, increasing investment in personalized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Significant trends for this period encompass the growing adoption of mechanical ventilation and ECMO devices, an escalating prevalence of ARDS resulting from COVID-19 and other respiratory conditions, the expanded application of advanced diagnostic tests for early identification, the enlargement of critical care and ICU facilities, and a dedicated focus on personalized and supportive care management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Drivers Are Influencing Production Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

The acute respiratory distress syndrome (ARDS) market is anticipated to expand due to a rising prevalence of respiratory illnesses. Respiratory illnesses encompass various medical conditions impacting the respiratory system, specifically the airways and lungs, often resulting in breathing difficulties. A key force behind the expansion of the acute respiratory distress syndrome (ARDS) market is the growing incidence of these conditions, exemplified by diseases such as COVID-19. This surge in respiratory ailments is projected to boost the need for ARDS treatments and therapies, consequently fostering market development. For example, data from October 2024, published by the National Asthma Council, an Australia-based non-profit body, revealed that Australia registered 474 asthma-related deaths in 2023, with 325 being females and 149 males. This mortality count closely mirrors the 473 asthma-related deaths documented in 2022, indicating a stable pattern in asthma fatalities over those two years. Consequently, the escalating occurrence of respiratory illnesses is a significant catalyst for the growth of the acute respiratory distress syndrome (ARDS) market.

Which Segment Groups Are Influencing The Acute Respiratory Distress Syndrome (ARDS) Market?

The acute respiratory distress syndrome (ards) market covered in this report is segmented –

1) By Type: Diagnosis, Treatment

2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:

1) By Diagnosis: Imaging Tests, Blood Tests

2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

Which Trends Are Guiding The Evolution Of The Acute Respiratory Distress Syndrome (ARDS) Market?

Major companies operating in the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to improve patient survival and mitigate inflammation. These immune modulators are therapies designed to restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by replenishing gelsolin, which is a critical immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be accessible through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for expedited regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially accelerating its time to market and providing a novel therapeutic choice for patients with limited alternatives.

Who Are The Core Companies Influencing Trends In The Acute Respiratory Distress Syndrome (ARDS) Market?

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Which Regions Are Projected To Dominate The Acute Respiratory Distress Syndrome (ARDS) Market In The Coming Years?

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Acute Respiratory Distress Syndrome (ARDS) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

Acute Coronary Syndrome Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Severe Acute Respiratory Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Respiratory Disease Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795